Who
Jennifer L. Taubert
Director
Company insider
Files Form 4 as: Director, McDonald's; EVP, WWC. Innovative Medicine, Johnson & Johnson.
In numbers
- Trades disclosed
- 139
- Buys
- 0
- Sells
- 4
- Bought
- $0
- Sold
- $40.8M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 8 Feb 2019
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | MCD McDonald'soption or derivative · Restaurants | SEC FORM 4 Code A | $30K129.9 at $230.94 | filing |
| 17 Aug 2026filed 18 Aug 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code M | $1.7M15,000 at $115.67 | filing |
| 17 Aug 2026filed 18 Aug 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $4.0M15,000 at $263.36 | filing |
| 17 Aug 2026filed 18 Aug 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 17 Aug 2026filed 18 Aug 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 17 Aug 2026filed 18 Aug 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code M | $1.7M15,000 at $115.67 | filing |
| 17 Aug 2026filed 18 Aug 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Sold | $4.0M15,000 at $263.36 | filing |
| 30 Jun 2026filed 2 Jul 2026 | MCD McDonald'soption or derivative · Restaurants | SEC FORM 4 Code A | $30K110.99 at $270.31 | filing |
| 30 Jun 2026filed 2 Jul 2026 | MCD McDonald'soption or derivative · Restaurants | SEC FORM 4 Code A | $30K110.99 at $270.31 | filing |
| 31 Mar 2026filed 2 Jul 2026 | MCD McDonald'soption or derivative · Restaurants | SEC FORM 4 Code A | $30K96.53 at $310.79 | filing |
| 31 Mar 2026filed 2 Jul 2026 | MCD McDonald'soption or derivative · Restaurants | SEC FORM 4 Code A | $30K96.53 at $310.79 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,594 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,847 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —54,869 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —3,940 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,594 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,847 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —54,869 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & Johnsonoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —3,940 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | JNJ Johnson & JohnsonPharmaceuticals | SEC FORM 4 Code M | —1,594 at $0.00 | filing |
News
Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trialJNJ · indiatimes.com · 24 Oct 2026"No Industry Has Been as Criminal as Big Pharma": Gardiner Harris on Johnson & Johnson – Sri Lanka GuardianJNJ · slguardian.org · 24 Oct 2026Capital Group Core Balanced ETF (NYSE: CGBL) Opens New Position In Johnson & Johnson (NYSE: JNJ)JNJ · foreignpolicyjournal.com · 23 Oct 2026
0 headlines in the last 90 days name Jennifer L. Taubert; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.